Clinical Trials
24 trialsNCT07007182 2026-05-01
Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
NCT05867121 2026-04-27
A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010
Genentech, Inc.
Phase 1 Active not recruiting
NCT06461910 2026-03-03
Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT07165847 2025-09-10
Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Recruiting
NCT06603974 2024-09-19
EASOBFGE
Xijing Hospital
Phase NA Not yet recruiting
NCT05498766 2024-06-24
Effect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer Patients
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 4 Not yet recruiting
NCT01515748 2023-12-13
PRODIGY
Sanofi
Phase 3 Completed
NCT05914610 2023-08-25
Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer
Fujian Medical University
Phase 3 Not yet recruiting
NCT05325528 2023-02-01
Study of Tislelizumab in Combination With SOX for the Treatment of Gastric Cancer With Liver Metastases
Zhejiang University
Phase 2/3 Unknown
NCT05594381 2022-10-26
A Biomarker Study for Predicting the Efficacy of Neoadjuvant Sintilimab Plus SOX for Gastric Adenocarcinoma.
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT03001726 2022-05-06
To Observe the Efficacy and Safety by Comparing Chemotherapy(Docetaxel, Oxaliplatin Plus S1 ) Followed With Radical Resection Versus Chemotherapy Alone in Advanced Gastric Cancer With Single Non-curable Factor.
Shanghai Zhongshan Hospital
Unknown
NCT03154983 2020-12-09
The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer
Zhongnan Hospital
Phase 2 Unknown
NCT04135781 2020-03-23
Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage â…¢ Gastric Cancer
Zhejiang Cancer Hospital
Phase 3 Unknown
NCT01516944 2020-02-13
Perioperative Chemotherapy for Potentially Resectable Gastric Cancer
Hebei Medical University
Phase 2/3 Completed
NCT04202484 2019-12-17
Tripletrumab Combined With Oxaliplatin and Teggio (SOX) in First-line Treatment of Gastric and Gastroesophageal Junction Adenocarcinoma
RenJi Hospital
Phase 2 Unknown
NCT03941561 2019-05-31
S-1 for 9 Months Versus 1 Year for Stage II Gastric Cancer (SMAC）
Fudan University
Phase 3 Recruiting
NCT03475615 2018-03-23
A Study of Intraperitoneal Paclitaxel in Combination With SOX Compared With SOX Alone in Gastric Cancer With Malignant Ascites
Fudan University
Phase 3 Unknown
NCT02527785 2017-08-23
Study of Oxaliplatin, Irinotecan, and S-1 in Gastric Cancer
Hallym University Medical Center
Phase 2 Completed
NCT02903498 2016-10-12
The Maintenance Treatment of UFT in Advanced Gastric Cancer
Fudan University
Phase 2 Completed
NCT02623153 2015-12-07
Comparison Between XELOX and S1, Oxaliplatin and Docetaxel as Neoadjuvant Chemotherapy for Gastric Cancer
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT02090153 2014-03-18
Study of S-1 Plus LV for Advanced Gastric Cancer
Sun Yat-sen University
Phase 2 Completed
NCT01198392 2011-07-25
Trial of S-1 Plus Cisplatin in Gastric Cancer
Sun Yat-sen University
Phase 3 Unknown
NCT00152243 2011-07-07
A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of Uracil- Tegafur (UFT) Compared With Surgery Alone (NSAS-GC)
Taiho Pharmaceutical Co., Ltd.
Phase 3 Completed
NCT00503321 2009-01-23
eNCIT-Japan
Eastern Network of Cancer Immunological Therapy, Japan
Phase 2/3 Terminated